<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; with</title>
	<atom:link href="http://www.tapanray.in/tag/with/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Does the Landmark Glivec Judgment Discourage Innovation in India?</title>
		<link>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-the-landmark-glivec-judgment-discourage-innovation-in-india</link>
		<comments>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/#comments</comments>
		<pubDate>Mon, 08 Apr 2013 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[191]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Case]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Cipal]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[gefitinib. Roche]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[highcourt]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[interpretation]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Janumet]]></category>
		<category><![CDATA[Januvia]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[knowledge]]></category>
		<category><![CDATA[landmark]]></category>
		<category><![CDATA[medicines. imatinib]]></category>
		<category><![CDATA[mesylate]]></category>
		<category><![CDATA[MSD]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[pegasys]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revocation]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[stutent]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[with]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[Zita]]></category>
		<category><![CDATA[Zita-Met]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2150</guid>
		<description><![CDATA[No, I do not think so. The 112 pages well articulated judgment of the Supreme Court of India delivered on April 1, 2013, does not even remotely discourage innovation in India, including much talked about ‘incremental innovation’. This landmark judgment &#8230; <a href="http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nutraceuticals with Therapeutic Claims: A Vulnerable Growing Bubble Protected by Faith and Hope of Patients</title>
		<link>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients</link>
		<comments>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/#comments</comments>
		<pubDate>Mon, 27 Aug 2012 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Bubble]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Claims]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[Faith]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hope]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Protected]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=45</guid>
		<description><![CDATA[Today a growing number of particularly the aging population wants to live a healthy life without consuming much of chemical drugs, which in turn is becoming a key growth driver for nutraceutical products across the world. Further, increasing interest towards &#8230; <a href="http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Finance Ministry Disallows Expenses on &#8216;Freebies&#8217; to Doctors by Pharma Companies in line with MCI Guidelines: A Possible Game Changer?</title>
		<link>http://www.tapanray.in/finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer</link>
		<comments>http://www.tapanray.in/finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer/#comments</comments>
		<pubDate>Mon, 06 Aug 2012 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Disallows]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Expenses]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[Freebies]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Possible]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=56</guid>
		<description><![CDATA[Things are unfolding reasonably faster now related to the financial relationship between the pharmaceutical companies and the medical profession. All these issues are getting increasingly dragged into the public debate where government can no longer play the role of a &#8230; <a href="http://www.tapanray.in/finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bollywood Matinee Idol Pontifies on Pharma FDI with Razzmatazz: Exploring Facts</title>
		<link>http://www.tapanray.in/bollywood-matinee-idol-pontifies-on-pharma-fdi-with-razzmatazz-exploring-facts/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=bollywood-matinee-idol-pontifies-on-pharma-fdi-with-razzmatazz-exploring-facts</link>
		<comments>http://www.tapanray.in/bollywood-matinee-idol-pontifies-on-pharma-fdi-with-razzmatazz-exploring-facts/#comments</comments>
		<pubDate>Mon, 09 Jul 2012 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aamir]]></category>
		<category><![CDATA[Bollywood]]></category>
		<category><![CDATA[Exploring]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Idol]]></category>
		<category><![CDATA[Khan]]></category>
		<category><![CDATA[Matinee]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pontifies]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Razzmatazz]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=69</guid>
		<description><![CDATA[It has been widely reported  by the media that Bollywood matinee idol Aamir Khan was invited by the Parliamentary Standing Committee  (PSC) on commerce to express his views on Foreign Direct Investments (FDI) in the pharmaceutical sector of India on &#8230; <a href="http://www.tapanray.in/bollywood-matinee-idol-pontifies-on-pharma-fdi-with-razzmatazz-exploring-facts/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/bollywood-matinee-idol-pontifies-on-pharma-fdi-with-razzmatazz-exploring-facts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Counterfeit Drugs and ACTA: Should the global menace related to &#8216;Public Health and Safety&#8217; be mixed-up with Intellectual Property Rights?</title>
		<link>http://www.tapanray.in/counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights</link>
		<comments>http://www.tapanray.in/counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights/#comments</comments>
		<pubDate>Mon, 02 Jul 2012 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ACTA]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[menace]]></category>
		<category><![CDATA[mixed-up]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[related]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=72</guid>
		<description><![CDATA[Here in this article, I am talking about drugs or medicines, which you may ultimately land up into buying, quite innocently though, against your doctor’s prescriptions, without having an inkling that these drugs can push you into serious health hazards, &#8230; <a href="http://www.tapanray.in/counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/counterfeit-drugs-and-acta-should-the-global-menace-related-to-public-health-and-safety-be-mixed-up-with-intellectual-property-rights/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Increasing Healthcare Consumption in India with equity</title>
		<link>http://www.tapanray.in/increasing-healthcare-consumption-in-india-with-equity/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=increasing-healthcare-consumption-in-india-with-equity</link>
		<comments>http://www.tapanray.in/increasing-healthcare-consumption-in-india-with-equity/#comments</comments>
		<pubDate>Sun, 13 May 2012 23:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Consumption]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Increasing]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[medicines. tapan]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sectors]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=94</guid>
		<description><![CDATA[Along with the economic progress of India, healthcare consumption of the population of the country is also increasing at a reasonably faster pace. According to McKinsey India Report, 2007, the share of average household healthcare consumption has increased from 4 &#8230; <a href="http://www.tapanray.in/increasing-healthcare-consumption-in-india-with-equity/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/increasing-healthcare-consumption-in-india-with-equity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reaping rich harvest with less moaning and bagful of creative ideas from emerging Rural Markets of India</title>
		<link>http://www.tapanray.in/reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india</link>
		<comments>http://www.tapanray.in/reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india/#comments</comments>
		<pubDate>Mon, 07 May 2012 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[bagful]]></category>
		<category><![CDATA[BPL]]></category>
		<category><![CDATA[creative]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[harvest]]></category>
		<category><![CDATA[ideas]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[janaaushadhi]]></category>
		<category><![CDATA[less]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[moaning]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reaping]]></category>
		<category><![CDATA[rich]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[urban]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=97</guid>
		<description><![CDATA[About 72 percent of the population and 135 million households of India live in the rural areas of the country. Many of them are poor. Definition of &#8216;Rural&#8217;: Agencies of the Government of India like, National Council of Applied Economic &#8230; <a href="http://www.tapanray.in/reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Getting unfolded a global opportunity for India with Biosimilar Drugs</title>
		<link>http://www.tapanray.in/getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs</link>
		<comments>http://www.tapanray.in/getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs/#comments</comments>
		<pubDate>Mon, 19 Dec 2011 00:20:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Getting]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[unfolded]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=159</guid>
		<description><![CDATA[Over a period of time, the trend of a disease treatment process is becoming more targeted and personalized to improve effectiveness of both diagnosis and treatment. Biotechnology being the key driver to this trend, India should not fall out of &#8230; <a href="http://www.tapanray.in/getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Explore the Emerging Markets with the &#8216;Wings of Courage&#8217;.</title>
		<link>http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=explore-the-emerging-markets-with-the-wings-of-courage</link>
		<comments>http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/#comments</comments>
		<pubDate>Mon, 07 Mar 2011 00:30:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Courage]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[Explore]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Wings]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=293</guid>
		<description><![CDATA[Overall growth rate of the global pharmaceutical industry is currently hovering around 5%. Similar situation has been prevailing since last several years. There is no indication of acceleration of growth rate from any of the top 3 regions of the &#8230; <a href="http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indian Pharmaceutical Industry could well be a contender for global supremacy by the next decade, competing effectively with China</title>
		<link>http://www.tapanray.in/indian-pharmaceutical-industry-could-well-be-a-contender-for-global-supremacy-by-the-next-decade-competing-effectively-with-china/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-pharmaceutical-industry-could-well-be-a-contender-for-global-supremacy-by-the-next-decade-competing-effectively-with-china</link>
		<comments>http://www.tapanray.in/indian-pharmaceutical-industry-could-well-be-a-contender-for-global-supremacy-by-the-next-decade-competing-effectively-with-china/#comments</comments>
		<pubDate>Mon, 22 Nov 2010 00:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[competing]]></category>
		<category><![CDATA[contender]]></category>
		<category><![CDATA[could]]></category>
		<category><![CDATA[CRAM]]></category>
		<category><![CDATA[decade]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[effectively]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[next]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[refor]]></category>
		<category><![CDATA[supremacy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[well]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=345</guid>
		<description><![CDATA[By the next decade of this millennium both India and China are expected to be the top two emerging markets of the world in the pharmaceutical sector, registering a scorching pace of growth all around. The quality of consistency and &#8230; <a href="http://www.tapanray.in/indian-pharmaceutical-industry-could-well-be-a-contender-for-global-supremacy-by-the-next-decade-competing-effectively-with-china/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-pharmaceutical-industry-could-well-be-a-contender-for-global-supremacy-by-the-next-decade-competing-effectively-with-china/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
